Excess
iron deposition in vital organs is the main cause of morbidity and mortality in patients affected by β-
thalassemia and hereditary
hemochromatosis. In both disorders, inappropriately low levels of the liver
hormone hepcidin are responsible for the increased
iron absorption, leading to toxic
iron accumulation in many organs. Several studies have shown that targeting
iron absorption could be beneficial in reducing or preventing
iron overload in these 2 disorders, with promising preclinical data. New approaches target Tmprss6, the main suppressor of
hepcidin expression, or use minihepcidins, small
peptide hepcidin agonists. Additional strategies in β-
thalassemia are showing beneficial effects in ameliorating ineffective erythropoiesis and
anemia. Due to the suppressive nature of the erythropoiesis on
hepcidin expression, these approaches are also showing beneficial effects on
iron metabolism. The goal of this review is to discuss the major factors controlling
iron metabolism and erythropoiesis and to discuss potential novel therapeutic approaches to reduce or prevent
iron overload in these 2 disorders and ameliorate
anemia in β-
thalassemia.